Capital Research Global Investors / ABT
Capital Research Global Investors’s Abbott Laboratories Position
Does Capital Research Global Investors own Abbott Laboratories (ABT)? Yes — 49.78M shares worth $5.1B (+0.79% of its 13F portfolio) as of Q1 2026, up from 39.17M shares the prior filed quarter.
Position Value
$5.1B
Q1 2026
Shares
49.78M
% of Portfolio
+0.79%
Quarters Held
30
currently held
Position History ABT
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q1 2026 | 49.78M | $5.1B | +0.79% |
| Q4 2025 | 39.17M | $4.9B | +0.91% |
| Q3 2025 | 38.77M | $5.2B | +0.97% |
| Q2 2025 | 41.77M | $5.7B | +1.14% |
| Q1 2025 | 50.73M | $6.7B | +1.46% |
| Q4 2024 | 54.10M | $6.1B | +1.26% |
| Q3 2024 | 53.30M | $6.1B | +1.26% |
| Q2 2024 | 57.24M | $5.9B | +1.31% |
| Q1 2024 | 83.98M | $9.5B | +2.16% |
| Q4 2023 | 86.59M | $9.5B | +2.34% |
| Q3 2023 | 79.06M | $7.7B | +2.11% |
| Q2 2023 | 77.23M | $8.4B | +2.26% |
| Q1 2023 | 76.40M | $7.7B | +2.21% |
| Q4 2022 | 76.79M | $8.4B | +2.55% |
| Q3 2022 | 78.81M | $7.6B | +2.51% |
| Q2 2022 | 80.10M | $8.7B | +2.71% |
| Q1 2022 | 80.68M | $9.5B | +2.36% |
| Q4 2021 | 84.13M | $11.8B | +2.62% |
| Q3 2021 | 84.45M | $10.0B | +2.33% |
| Q2 2021 | 85.82M | $9.9B | +2.32% |
| Q1 2021 | 85.79M | $10.3B | +2.52% |
| Q4 2020 | 86.39M | $9.5B | +2.46% |
| Q3 2020 | 87.41M | $9.5B | +2.86% |
| Q2 2020 | 87.42M | $8.0B | +2.53% |
| Q1 2020 | 95.87M | $7.6B | +2.97% |
| Q4 2019 | 113.69M | $9.9B | +2.96% |
| Q3 2019 | 113.07M | $9.5B | +3.10% |
| Q2 2019 | 116.79M | $9.8B | +3.12% |
| Q1 2019 | 115.57M | $9.2B | +2.93% |
| Q4 2018 | 121.93M | $8.8B | +3.07% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Capital Research Global Investors’s full portfolio or all institutional holders of ABT.